Immunicum AB

Immunicum hires Lise-Lotte Hallbäck as new CFO

Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer

Immunicum clarifies statement on liver cancer study

Immunicum updates safety and survival data in liver cancer study with INTUVAX

Immunicum: Management sells a small amount of their shares

Immunicum supplies NCI research with technology for CRISPR/Cas9 system

Immunicum’s Chief Scientific Officer presented the technology behind the cancer vaccine INTUVAX at a symposium at Karolinska Institutet in conjunction with world-leading researchers in immunology

Immunicum receives approval to start phase II study with the therapeutic cancer vaccine INTUVAX

Patent for the production of Immunicum’s therapeutic cancer vaccines to be granted in Europe

Immunicum: Patent application related to Immunicum’s therapeutic cancer vaccine SUBCUVAX to be granted in the US

Immunicum: The patent application relating to activation of Immunicum’s COMBIG-cells for therapeutic cancer vaccination will be granted in the US

Immunicum reports continued promising survival data for INTUVAX-treated renal cancer patients

Immunicum presents safety and survival data from a clinical phase I/II study with INTUVAX in patients with liver cancer

Immunicum’s CSO Alex Karlsson-Parra awarded the Athena Prize

Immunicum acquires patent for oncolytic therapy and further development of SUBCUVAX

Immunicum presents updated survival data for INTUVAX-treated renal cancer patients

Immunicum’s rights issue oversubscribed

Immunicum announces INTUVAX phase I/II data at ASCO 2014

Immunicum publishes supplement to prospectus for rights issue

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell carcinoma

Immunicum – INTUVAX abstract at ASCO 2014

Date for Immunicum’s interim report for the period July 2013 – March 2014 changed

Immunicum has completed a private placement and resolved on a fully underwritten rights issue

Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data

Immunicum’s abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago

Immunicum reports promising preclinical results for its CD70 technology in adoptive immunotherapy

Immunicum: Interim Report July – December 2013

Immunicum reports positive phase I/II-data for the therapeutic cancer vaccine INTUVAX® in the treatment of kidney cancer

Immunicum : Sven Andréasson new Board member

Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.